A report released today by Bankhaus Lampe KG about Bayer (ETR:BAYN) raises the target price to 103.00EUR
- Updated: September 15, 2016
Bankhaus Lampe KG bumped the target stock price of Bayer (ETR:BAYN) to 103EUR, indicating a possible upside of 0.10%.
Previously on 8/29/2016, Citigroup Corp. released a statement on Bayer(ETR:BAYN) upped the target price from 0.00EUR to 120.00EUR that suggested an upside of 0.24%.
Just yesterday Bayer (ETR:BAYN) traded 7.14% lower at 93.66EUR. BAYN’s 50-day moving average is 0.04EUR and its 200-day average is 0.03EUR. With the last close up 1.82% relative to the 200-day average, compared to the S&P 500 which has decreased -0.01% over the same time. 10,000 shares of the stock were exchanged, up from ann avg. trading volume of 211.
See Chart Below:
Bayer has a 52 week low of 0.03EUR and a one-year high of 0.04EUR . The company’s market cap is currently 0.0 EUR.
Brief Synopsis On Bayer (ETR:BAYN)
Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures. The Consumer Health segment is engaged in the development of over-the-counter medications, dermatology products and nutritional supplements. The Crop Science segment is engaged in the development of product portfolio in the areas of seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural pest control. The Animal Health segment is engaged in the development of veterinary medicines and animal grooming products. Covestro is engaged in the development of raw materials for polyurethanes; polycarbonate resins and sheets; raw materials for coatings, and adhesives and sealants; and selected chemical intermediates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.